Close

move up move left move right move bottom

Formulary Coverage

Comprehensive access support

Janssen is dedicated to making XARELTO® affordable and accessible for all patients. With widespread inclusion on hospital, managed care, and PBM formularies, >95% of commercial and Medicare patients are covered at the lowest branded co-pay.1

To see the coverage for your patients, enter your ZIP code. Your results will appear below.

Janssen CarePath Savings Program for XARELTO®

  • Eligible patients with an approved chronic indication for XARELTO®
    (10 mg, 15 mg or 20 mg)

  • Eligible commercially insured patients can have as little as a $10 co-pay per month for their XARELTO® medication costs with up to $3,400 maximum program benefit per calendar year. Subject to a monthly limit. Not valid for patients using Medicare, Medicare Part D, Medicaid, or other government-funded program.

For eligibility requirements, visit Janssen CarePath or call 877-CarePath (877-227-3728).


Other Resources

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if they might qualify for assistance, please have your patient contact a JJPAF program specialist at 1-800-652-6227 (9 am to 6 pm ET) or visit the foundation website at www.jjpaf.org.

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and/or PE in patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

Reference:

  1. Data on file. Janssen Pharmaceuticals, Inc. Source: Managed Markets Insight and Technology, LLCTM, a trademark of MMIT, as of September 15, 2017, and is subject to change.